​

Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALNY Stock Forecast

Alnylam Pharmaceuticals stock forecast is as follows: an average price target of $310.60 (represents a 26.55% upside from ALNY’s last price of $245.44) and a rating consensus of 'Buy', based on 22 wall street analysts offering a 1-year stock forecast.

ALNY Price Target

The average price target for Alnylam Pharmaceuticals (ALNY) is $310.60 based on 1-year price targets from 22 Wall Street analysts in the past 3 months, with a price target range of $400.00 to $250.00. This represents a potential 26.55% upside from ALNY's last price of $245.44.

ALNY Analyst Ratings

Buy

According to 22 Wall Street analysts, Alnylam Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ALNY stock is 0 'Strong Buy' (0.00%), 17 'Buy' (77.27%), 4 'Hold' (18.18%), 1 'Sell' (4.55%), and 0 'Strong Sell' (0.00%).

Alnylam Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024Whitney IjemCanaccord Genuity$336.00$294.8713.95%36.90%
Oct 01, 2024Whitney IjemCanaccord Genuity$366.00$273.6933.73%49.12%
Sep 27, 2024Tazeen AhmadBank of America Securities$307.00$274.9111.67%25.08%
Aug 27, 2024Kostas BiliourisBMO Capital$300.00$269.3111.40%22.23%
Aug 26, 2024Luca IssiRBC Capital$300.00$271.4310.53%22.23%
Aug 16, 2024Salveen RichterGoldman Sachs$370.00$262.7040.85%50.75%
Jul 08, 2024Whitney IjemCanaccord Genuity$357.00$253.8640.63%45.45%
Jun 28, 2024Esther RajaveluUBS$288.00$247.0016.60%17.34%
Jun 27, 2024Luca IssiRBC Capital$265.00$245.178.09%7.97%
Jun 27, 2024Paul MatteisStifel Nicolaus$295.00$247.4019.24%20.19%
Jun 25, 2024Liisa BaykoEvercore ISI$260.00$222.9016.64%5.93%
Jun 25, 2024Luca IssiRBC Capital$250.00$222.9012.16%1.86%
Jun 24, 2024Andrew GallerMorgan Stanley$250.00$224.7011.26%1.86%
Jun 24, 2024Patrick TrucchioH.C. Wainwright$400.00$227.0576.17%62.97%
Jun 24, 2024Paul MatteisStifel Nicolaus$247.00$227.928.37%0.64%
Jun 12, 2024Luca IssiRBC Capital$235.00$156.4350.23%-4.25%
Apr 08, 2024Kostas BiliourisBMO Capital$234.00$156.5949.43%-4.66%
Dec 15, 2022Edward TenthoffPiper Sandler$253.00$229.3710.30%3.08%
Jul 12, 2022Olivia BrayerCantor Fitzgerald$175.00$145.8519.99%-28.70%
Jun 14, 2022Edward TenthoffPiper Sandler$208.00$135.8253.14%-15.25%
May 02, 2022H.C. Wainwright$430.00$133.43222.27%75.20%
Apr 29, 2022BMO Capital$166.00$137.8020.46%-32.37%
Apr 29, 2022Citigroup$211.00$136.6754.39%-14.03%
Apr 29, 2022Leerink Partners$96.00$143.16-32.94%-60.89%
Apr 25, 2022Morgan Stanley$178.00$167.006.59%-27.48%
Feb 11, 2022Zhiqiang ShuBerenberg Bank$154.00$150.762.15%-37.26%
Feb 11, 2022Gary NachmanBMO Capital$175.00$150.7616.08%-28.70%
Feb 10, 2022Luca IssiRBC Capital$225.00$150.8649.14%-8.33%
Feb 03, 2022Debjit ChattopadhyayGuggenheim$170.00$142.5119.29%-30.74%
Jan 26, 2022Tazeen AhmadBank of America Securities$209.00$130.1260.62%-14.85%
Jan 23, 2022Maury RaycroftJefferies$205.00$136.5350.15%-16.48%
Dec 13, 2021Ritu BaralCowen & Co.$250.00$186.4234.11%1.86%
Nov 22, 2021Salveen RichterGoldman Sachs$273.00$187.0145.98%11.23%
Oct 29, 2021Esther RajaveluUBS$211.00$159.5632.24%-14.03%
Oct 29, 2021Alethia YoungCantor Fitzgerald$275.00$159.5672.35%12.04%
Oct 29, 2021Maneka MirchandaneyEvercore ISI$190.00$159.5619.08%-22.59%
Oct 28, 2021Gena WangBarclays$210.00$162.1429.52%-14.44%

The latest Alnylam Pharmaceuticals stock forecast, released on Oct 24, 2024 by Whitney Ijem from Canaccord Genuity, set a price target of $336.00, which represents a 13.95% increase from the stock price at the time of the forecast ($294.87), and a 36.90% increase from ALNY last price ($245.44).

Alnylam Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts-317
Avg Price Target-$336.33$297.65
Last Closing Price$245.44$245.44$245.44
Upside/Downside-100.00%37.03%21.27%

In the current month, the average price target of Alnylam Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Alnylam Pharmaceuticals's last price of $245.44. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024Canaccord GenuityBuyBuyHold
Oct 21, 2024Cowen & Co.BuyBuyHold
Oct 18, 2024H.C. WainwrightBuyBuyHold
Oct 01, 2024Canaccord GenuityBuyBuyHold
Sep 27, 2024Bank of America SecuritiesBuyBuyHold
Sep 03, 2024OppenheimerPerformPerformHold
Sep 03, 2024Wolfe ResearchNegativeNegativeHold
Sep 03, 2024Cowen & Co.BuyBuyHold
Sep 03, 2024H.C. WainwrightBuyBuyHold
Sep 03, 2024BarclaysOverweightOverweightHold
Aug 27, 2024BMO CapitalOutperformOutperformHold
Aug 26, 2024RBC CapitalOutperformOutperformHold
Aug 16, 2024Goldman SachsNeutralBuyUpgrade
Aug 02, 2024RBC CapitalOutperformOutperformHold
Aug 02, 2024BarclaysOverweightOverweightHold
Jul 08, 2024Canaccord GenuityBuyBuyHold
Jun 28, 2024UBSBuyBuyHold
Jun 25, 2024Evercore ISIOutperformOutperformHold
Jun 25, 2024Cowen & Co.BuyBuyHold
Jun 25, 2024Wells FargoEqual-WeightEqual-WeightHold
Jun 25, 2024CitigroupBuyBuyHold
Jun 25, 2024BarclaysOverweightOverweightHold
Jun 24, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jun 24, 2024H.C. WainwrightBuyBuyHold
Jun 24, 2024BMO CapitalOutperformOutperformHold
Jun 12, 2024RBC CapitalOutperformOutperformHold
Apr 08, 2024JMP SecuritiesPositiveInitialise
Apr 08, 2024William BlairOutperformOutperformHold
Apr 08, 2024BMO CapitalOutperformOutperformHold
Feb 16, 2024Goldman SachsNeutralDowngrade
Dec 22, 2023William BlairOutperformOutperformHold
Oct 11, 2023Deutsche BankBuyBuyHold
Sep 14, 2023Cantor FitzgeraldNeutralNeutralHold
May 05, 2023BMO CapitalMarket PerformOutperformUpgrade
Dec 15, 2022Piper SandlerOverweightOverweightHold
Sep 09, 2022OppenheimerOutperformOutperformHold
Jul 12, 2022Cantor FitzgeraldNeutralInitialise
Jun 14, 2022Piper SandlerOverweightOverweightHold
Apr 29, 2022BMO CapitalMarket PerformMarket PerformHold
Apr 29, 2022CitigroupBuyBuyHold
Apr 29, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Apr 29, 2022SVB LeerinkMarket PerformMarket PerformHold
Apr 26, 2022Stifel NicolausBuyBuyHold
Feb 23, 2022Morgan StanleyOverweightOverweightHold
Jan 03, 2022Piper SandlerOverweightUpgrade
Nov 22, 2021NeedhamBuyBuyHold

Alnylam Pharmaceuticals's last stock rating was published by Canaccord Genuity on Oct 24, 2024. The company gave ALNY a "Buy" rating, the same as its previous rate.

Alnylam Pharmaceuticals Financial Forecast

Alnylam Pharmaceuticals Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$750.53M-$319.29M$335.04M$264.31M$224.82M$213.26M$258.54M$187.63M$220.55M$177.57M$163.56M$125.85M$103.96M$99.48M$71.68M$70.06M
Avg Forecast$997.48M$944.74M$823.90M$777.35M$780.64M$658.42M$569.77M$547.38M$580.61M$532.91M$447.22M$428.01M$436.92M$396.76M$332.28M$312.27M$313.13M$291.66M$255.56M$240.95M$233.61M$218.72M$192.05M$168.50M$146.64M$119.05M$98.76M$91.74M$71.60M$57.17M
High Forecast$1.14B$1.08B$939.91M$886.81M$890.56M$751.13M$650.00M$584.75M$665.51M$539.25M$447.22M$428.01M$483.30M$647.63M$379.06M$356.24M$357.23M$291.66M$255.56M$240.95M$233.61M$218.72M$192.05M$168.50M$146.64M$119.05M$98.76M$91.74M$71.60M$57.17M
Low Forecast$902.17M$854.47M$745.18M$703.08M$706.05M$595.51M$515.33M$499.40M$546.46M$526.57M$447.22M$428.01M$371.99M$327.97M$300.53M$282.43M$283.22M$291.66M$255.56M$240.95M$233.61M$218.72M$192.05M$168.50M$146.64M$119.05M$98.76M$91.74M$71.60M$57.17M
# Analysts33454527168510111788771271489151099955
Surprise %-------------1.89%-1.02%1.07%0.91%0.88%0.89%1.11%0.86%1.15%1.05%1.12%1.06%1.05%1.08%1.00%1.23%

Alnylam Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 11 analysts is $436.92M, with a low forecast of $371.99M, and a high forecast of $483.30M. ALNY's average Quarter revenue forecast represents a -41.79% decrease compared to the company's last Quarter revenue of $750.53M (Sep 23).

Alnylam Pharmaceuticals EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527168510111788771271489151099955
EBITDA-------------$213.87M-$-143.41M$-177.11M$-234.69M$-168.50M$-142.59M$-202.03M$-140.74M$-132.75M$-143.90M$-194.20M$-204.95M$-132.88M$-159.16M$-254.57M$-181.39M
Avg Forecast$-761.67M$-721.40M$-629.12M$-593.58M$-596.09M$-502.76M$-435.07M$-417.97M$-443.35M$-406.93M$-341.49M$-207.18M$-333.63M$-302.96M$-253.72M$-188.35M$-320.71M$-223.23M$-195.60M$-171.23M$-178.80M$-167.40M$-146.99M$-155.94M$-112.24M$-91.12M$-75.59M$-188.16M$-54.80M$-43.76M
High Forecast$-688.89M$-652.47M$-569.01M$-536.86M$-539.13M$-454.72M$-393.50M$-381.34M$-417.27M$-402.09M$-341.49M$-165.75M$-284.05M$-250.43M$-229.48M$-150.68M$-256.57M$-223.23M$-195.60M$-136.98M$-178.80M$-167.40M$-146.99M$-124.75M$-112.24M$-91.12M$-75.59M$-150.53M$-54.80M$-43.76M
Low Forecast$-868.92M$-822.98M$-717.71M$-677.16M$-680.02M$-573.56M$-496.33M$-446.51M$-508.18M$-411.77M$-341.49M$-248.62M$-369.04M$-494.52M$-289.45M$-226.02M$-384.85M$-223.23M$-195.60M$-205.47M$-178.80M$-167.40M$-146.99M$-187.13M$-112.24M$-91.12M$-75.59M$-225.79M$-54.80M$-43.76M
Surprise %--------------0.71%-0.76%0.55%1.05%0.86%0.83%1.13%0.84%0.90%0.92%1.73%2.25%1.76%0.85%4.65%4.15%

11 analysts predict ALNY's average Quarter EBITDA for Dec 23 to be $-333.63M, with a high of $-284.05M and a low of $-369.04M. This is -256.00% lower than Alnylam Pharmaceuticals's previous annual EBITDA (Sep 23) of $213.87M.

Alnylam Pharmaceuticals Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527168510111788771271489151099955
Net Income-------------$147.75M-$-174.10M$-207.49M$-405.92M$-277.40M$-240.34M$-258.46M$-204.51M$-189.56M$-200.29M$-243.54M$-253.29M$-179.23M$-182.22M$-276.19M$-208.53M
Avg Forecast$189.36M$156.03M$77.73M$57.29M$-24.51M$-61.36M$-100.91M$-95.22M$-72.57M$-117.87M$-137.21M$-265.52M$-152.55M$-185.90M$-193.64M$-241.39M$-165.94M$-220.89M$-200.88M$-219.44M$-195.95M$-194.77M$-203.41M$-202.61M$-225.49M$-206.21M$-218.50M$-208.25M$-280.22M$-262.76M
High Forecast$224.03M$184.59M$91.96M$67.77M$-21.46M$-53.74M$-88.38M$-54.93M$76.02M$-103.23M$-120.16M$-212.42M$6.36M$91.58M$-169.59M$-193.11M$-132.75M$-220.89M$-200.88M$-175.55M$-195.95M$-194.77M$-203.41M$-162.09M$-225.49M$-206.21M$-218.50M$-166.60M$-280.22M$-262.76M
Low Forecast$165.84M$136.65M$68.08M$50.17M$-28.99M$-72.60M$-119.38M$-148.32M$-214.25M$-139.45M$-162.32M$-318.63M$-391.56M$-265.18M$-229.09M$-289.66M$-199.13M$-220.89M$-200.88M$-263.33M$-195.95M$-194.77M$-203.41M$-243.13M$-225.49M$-206.21M$-218.50M$-249.90M$-280.22M$-262.76M
Surprise %--------------0.79%-0.72%1.25%1.84%1.38%1.10%1.32%1.05%0.93%0.99%1.08%1.23%0.82%0.88%0.99%0.79%

Alnylam Pharmaceuticals's average Quarter net income forecast for Dec 23 is $-152.55M, with a range of $-391.56M to $6.36M. ALNY's average Quarter net income forecast represents a -203.25% decrease compared to the company's last Quarter net income of $147.75M (Sep 23).

Alnylam Pharmaceuticals SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527168510111788771271489151099955
SG&A-------------$199.18M-$183.66M$210.34M$235.86M$169.98M$154.47M$186.38M$142.07M$145.32M$146.86M$166.29M$167.47M$127.90M$126.76M$156.28M$120.35M
Avg Forecast$1.05B$998.94M$871.16M$821.94M$825.42M$696.19M$602.45M$578.78M$613.92M$563.48M$472.88M$170.66M$461.98M$419.52M$351.34M$155.14M$119.66M$308.39M$270.22M$141.04M$247.01M$231.27M$203.07M$148.56M$155.05M$125.88M$104.43M$97.00M$75.71M$60.45M
High Forecast$1.20B$1.14B$993.83M$937.68M$941.65M$794.22M$687.28M$618.29M$703.69M$570.18M$472.88M$204.79M$511.02M$684.78M$400.81M$186.17M$143.60M$308.39M$270.22M$169.25M$247.01M$231.27M$203.07M$178.27M$155.05M$125.88M$104.43M$97.00M$75.71M$60.45M
Low Forecast$953.93M$903.49M$787.93M$743.41M$746.55M$629.67M$544.89M$528.05M$577.81M$556.78M$472.88M$136.53M$393.33M$346.78M$317.77M$124.11M$95.73M$308.39M$270.22M$112.83M$247.01M$231.27M$203.07M$118.85M$155.05M$125.88M$104.43M$97.00M$75.71M$60.45M
Surprise %-------------0.47%-1.18%1.76%0.76%0.63%1.10%0.75%0.61%0.72%0.99%1.07%1.33%1.22%1.31%2.06%1.99%

Alnylam Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $461.98M, based on 11 Wall Street analysts, with a range of $393.33M to $511.02M. The forecast indicates a 131.95% rise compared to ALNY last annual SG&A of $199.18M (Sep 23).

Alnylam Pharmaceuticals EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527168510111788771271489151099955
EPS-------------$1.18-$-1.40$-1.68$-3.32$-2.29$-2.00$-2.16$-1.72$-1.61$-1.71$-2.09$-2.18$-1.56$-1.62$-2.47$-1.92
Avg Forecast$1.47$1.21$0.60$0.45$-0.19$-0.48$-0.78$-0.74$-0.56$-0.92$-1.07$-1.12$-1.19$-1.45$-1.51$-1.67$-1.86$-1.74$-1.59$-1.81$-1.55$-1.54$-1.61$-1.75$-1.78$-1.63$-1.72$-1.89$-2.21$-2.07
High Forecast$1.74$1.44$0.72$0.53$-0.17$-0.42$-0.69$-0.43$0.59$-0.80$-0.93$-0.98$0.05$0.71$-1.32$-1.46$-1.63$-1.74$-1.59$-1.81$-1.55$-1.54$-1.61$-1.75$-1.78$-1.63$-1.72$-1.89$-2.21$-2.07
Low Forecast$1.29$1.06$0.53$0.39$-0.23$-0.56$-0.93$-1.15$-1.67$-1.08$-1.26$-1.32$-3.04$-2.06$-1.78$-1.98$-2.20$-1.74$-1.59$-1.81$-1.55$-1.54$-1.61$-1.75$-1.78$-1.63$-1.72$-1.89$-2.21$-2.07
Surprise %--------------0.82%-0.84%0.90%1.90%1.44%1.11%1.40%1.12%1.00%0.98%1.17%1.34%0.90%0.86%1.12%0.93%

According to 11 Wall Street analysts, Alnylam Pharmaceuticals's projected average Quarter EPS for Dec 23 is $-1.19, with a low estimate of $-3.04 and a high estimate of $0.05. This represents a -200.54% decrease compared to ALNY previous annual EPS of $1.18 (Sep 23).

Alnylam Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
RAREUltragenyx Pharmaceutical$44.95$90.00100.22%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
WVEWave Life Sciences$14.45$22.1453.22%Buy
BMRNBioMarin Pharmaceutical$67.19$94.4340.54%Buy
INCYIncyte$69.40$90.1129.84%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
ALNYAlnylam Pharmaceuticals$246.58$310.6025.96%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy
PRQRProQR Therapeutics$2.94$3.6323.47%Buy
UTHRUnited Therapeutics$379.69$440.4015.99%Buy
HALOHalozyme Therapeutics$48.60$52.007.00%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy
EXELExelixis$34.69$30.89-10.95%Buy

ALNY Forecast FAQ

Is Alnylam Pharmaceuticals a good buy?

Yes, according to 22 Wall Street analysts, Alnylam Pharmaceuticals (ALNY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 17 'Buy' recommendations, accounting for 77.27% of ALNY's total ratings.

What is ALNY's price target?

Alnylam Pharmaceuticals (ALNY) average price target is $310.6 with a range of $250 to $400, implying a 26.55% from its last price of $245.44. The data is based on 22 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Alnylam Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for ALNY stock, the company can go up by 26.55% (from the last price of $245.44 to the average price target of $310.6), up by 62.97% based on the highest stock price target, and up by 1.86% based on the lowest stock price target.

Can Alnylam Pharmaceuticals stock reach $400?

ALNY's average twelve months analyst stock price target of $310.6 does not support the claim that Alnylam Pharmaceuticals can reach $400 in the near future.

What are Alnylam Pharmaceuticals's analysts' financial forecasts?

Alnylam Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.56B (high $2.88B, low $2.32B), average EBITDA is $-1.952B (high $-1.769B, low $-2.196B), average net income is $-282M (high $-219M, low $-369M), average SG&A $2.7B (high $3.04B, low $2.45B), and average EPS is $-2.193 (high $-1.699, low $-2.872). ALNY's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.54B (high $4.04B, low $3.2B), average EBITDA is $-2.706B (high $-2.447B, low $-3.087B), average net income is $480.41M (high $568.35M, low $420.74M), average SG&A $3.75B (high $4.27B, low $3.39B), and average EPS is $3.74 (high $4.42, low $3.27).

Did the ALNY's actual financial results beat the analysts' financial forecasts?

Based on Alnylam Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $1.83B, beating the average analysts forecast of $1.48B by 23.68%. Apple's EBITDA was $-282M, missing the average prediction of $-1.079B by -73.84%. The company's net income was $-440M, missing the average estimation of $-773M by -43.08%. Apple's SG&A was $0, missing the average forecast of $1.39B by -100.00%. Lastly, the company's EPS was $0, missing the average prediction of $-5.808 by -100.00%. In terms of the last quarterly report (Sep 2023), Alnylam Pharmaceuticals's revenue was $750.53M, beating the average analysts' forecast of $396.76M by 89.17%. The company's EBITDA was $213.87M, missing the average prediction of $-303M by -170.59%. Alnylam Pharmaceuticals's net income was $147.75M, missing the average estimation of $-186M by -179.48%. The company's SG&A was $199.18M, missing the average forecast of $419.52M by -52.52%. Lastly, the company's EPS was $1.18, missing the average prediction of $-1.446 by -181.62%